Ginkgo Bioworks Holdings, Inc.

# Signal Note: Casdin Capital Initiates Ginkgo Bioworks Position Casdin's entry into DNABW suggests conviction in synthetic biology cell engineering capabilities, likely tied to Ginkgo's pipeline programs in metabolic engineering and fermentation-based therapeutics. The $303K position size indicates exploratory exposure rather than conviction-scale betting, potentially reflecting wait-and-see stance ahead of near-term clinical readouts or partnership announcements in their precision fermentation platform. Key catalysts to monitor: clinical progression in their engineered cell therapy programs and revenue inflection from existing biotech partnerships.